Skip to Content
  • Previous Rank
    114
  • Revenues ($M)
    $103,444
  • Revenue Percent Change
    35.4%
  • Profits ($M)
    $4,220
  • Profits Percent Change
    118.4%
  • Assets ($M)
    $68,782
  • Employees
    302,500

Walgreens Boots Alliance has not looked healthy lately. Its partnerships with scandal-plagued Silicon Valley unicorn Theranos and controversial drug company Valeant have led to countless embarrassing headlines. Its acquisition of smaller rival Rite Aid may force it to sell off more drugstores than it really wants to. All the while, the company is still working to integrate the Alliance Boots acquisition last year and the turnover of most of its c-level executives. Still, Walgreens size gives it enormous clout with drugmakers, and the Boots products have been a big shot in the arm for its beauty business, allowing it to fend off CVS’ big push in that area. And its generic drug distribution contract with AmerisourceBergen has allowed it keep costs in check by streamlining how its gets its supply of drugs.

Company Information

Figures are for fiscal year ended Aug. 31, 2015. Reorganized as a holding company after acquiring the remaining 55% of Alliance Boots (Switzerland), Dec. 31, 2014. Prior year's figures are for Walgreen, now a subsidiary of the company.
CEO
Stefano Pessina
Sector
Food & Drug Stores
Industry
Food and Drug Stores
HQ Location
Deerfield, IL
Employees302,500
Websitehttp://www.walgreensbootsalliance.com
Years on Global 500 List22

Walgreens Boots Alliance Rank History

placeholder

Key Financials (last fiscal year)

($ Millions)% change
Revenues ($M)$103,44435.4%
Profits ($M)$4,220118.4%
Assets ($M)$68,782-
Total Stockholder Equity ($M)$30,861-

Profit Ratios

Profit as % of Revenues4.1%
Profits as % of Assets6.1%
Profits as % of Stockholder Equity13.7%